Beijing Sungen Biomedical Technology Co., Ltd.
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Beijing Sungen Biomedical Technology Co., Ltd. is an innovation-driven, clinical-stage biotechnology company founded in 2018, pioneering the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics, including mAbs, BsAbs, and ADCs. Sungen is committed to addressing critical unmet clinical needs through deep innovation in therapeutic antibodies, supported by a team of researchers and managers of successful biotechnology entrepreneur records, utilizing state-of-the-art in-house discovery and research platforms. Currently, Sungen is simultaneously focusing on research of antibody therapies in cardiology and oncology.
Company HQ City:
Beijing
Company HQ State:
Beijing
Company HQ Country:
China
Year Founded:
2018
Lead Product in Development:
SGT003 - A FIC-potential bsAb for higher efficacy and safety in next-generational backbone I/O therapy
SGC001 - A FIC-potential mAb to address ischemic reperfusion injury during PCI treatment
CEO
Changqing LIN
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
SGT003 is scheduled to obtain IND approval by June, 2026
SGC001 is scheduled to complete Phase II studies by mid 2027
What is your next catalyst (value inflection) update?
SGT003 is scheduled to obtain IND approval by both US FDA and China NMPA by June, 2026
SGC001 is scheduled to complete Phase II studies in China by mid 2027
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}